InMed Pharmaceuticals (INM) Net Cash Flow Growth (1y) (2020 - 2026)
InMed Pharmaceuticals (INM) Net Cash Flow Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 112.26% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -44.11% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -236.85% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -1,047.81% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -1,020.00% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -807.00% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -107.45% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 444.33% |
| 10 | InMed Pharmaceuticals | 6.04 Mn | 796,124.14 | - | -216.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -216.11% |
| Dec 31, 2025 | -9.83% |
| Sep 30, 2025 | -76.50% |
| Jun 30, 2025 | 721.59% |
| Mar 31, 2025 | 165.16% |
| Dec 31, 2024 | -17.07% |
| Sep 30, 2024 | 54.53% |
| Jun 30, 2024 | -48.80% |
| Mar 31, 2024 | -4.64% |
| Dec 31, 2023 | -171.02% |
| Sep 30, 2023 | -168.51% |
| Jun 30, 2023 | -348.26% |
| Mar 31, 2023 | 65.65% |
| Dec 31, 2022 | 164.03% |
| Sep 30, 2022 | -60.23% |
| Jun 30, 2022 | 113.33% |
| Mar 31, 2022 | -849.58% |
| Dec 31, 2021 | -178.81% |
| Sep 30, 2021 | 655.67% |
| Jun 30, 2021 | -49.48% |